JW Therapeutics said it completed a $90 million series A funding round led by investors including Temasek, Sequoia Capital China, and YuanMing Capital.
The Shanghai-based company is a joint venture created by Celgene Corp.-owned Juno Therapeutics Inc. and, China's WuXi AppTec Co., Ltd.
The venture is developing a chimeric antigen receptor T-cell, or CAR-T cell, therapy, JWCAR029, for treating blood cancers such as diffuse large B-cell lymphoma.
The investor consortium also included Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, and existing investors WuXi AppTec Group and Juno Therapeutics.
